Search Results

You are looking at 61 - 70 of 177 items for :

  • "tamoxifen" x
  • All content x
Clear All
Full access

David Scott Miller, Gini Fleming, and Marcus E. Randall

Oncology Group study . J Clin Oncol 1996 ; 14 : 357 – 361 . 19 Fiorica JV Brunetto VL Hanjani P . Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study

Full access

Susan M. Domchek, Jill E. Stopfer, and Timothy R. Rebbeck

: 1358 – 1365 . 45. Narod SA Brunet JS Ghadirian P . Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group . Lancet 2000 ; 356 : 1876

Full access

Melinda L. Telli, William J. Gradishar, and John H. Ward

tumors >0.5 cm, the NCCN Guidelines state as a category 1 recommendation that clinicians should “strongly consider the 21-gene assay.” The assay predicts the benefit of chemotherapy when added to tamoxifen as adjuvant therapy, regardless of menopausal

Full access

Sara H. Javid, L. Christine Fang, Larissa Korde, and Benjamin O. Anderson

breast-conserving surgery followed by radiation therapy, or mastectomy. 11 - 14 Tamoxifen is also considered as possible adjuvant therapy for patients with estrogen receptor-positive DCIS, both for reduction of local recurrence risk after breast

Full access

William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Jairam Krishnamurthy, Janice Lyons, P. Kelly Marcom, Jennifer Matro, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Jessica S. Young, Jennifer L. Burns, and Rashmi Kumar

-negative, advanced breast cancer were randomly assigned to first-line treatment with ribociclib or placebo with goserelin plus either a nonsteroidal AI or tamoxifen. 31 An improvement in PFS was seen with the addition of ribociclib (median PFS, 24 vs 13

Full access

receptor's ligand by blocking estrogen production via aromatase enzymatic inhibition. Tamoxifen is a nonsteroidal triphenylethylene derivative that acts as a SERM, with antagonist properties in mammary tissue. Tamoxifen has demonstrated efficacy and a

Full access

Rachel F. Dear, Kevin McGeechan, Megan B. Barnet, Alexandra L. Barratt, and Martin H.N. Tattersall

-consistent/NCCN-nonconsistent trials involved adjuvant endocrine therapy; 2 used a gonadotropin-releasing hormone (GnRH) agonist and tamoxifen in premenopausal women, and 4 used tamoxifen in postmenopausal women. A GnRH agonist with tamoxifen is included in the AGO guidelines for

Full access

Sharon H. Giordano, Anthony D. Elias, and William J. Gradishar

the global MONALEESA-7 trial of almost 700 premenopausal or perimenopausal women rendered postmenopausal. 17 Patients had received no prior endocrine therapy for metastatic disease; by physician's choice they received an AI (mostly) or tamoxifen, plus

Full access

Richard L. Theriault, J. Sybil Biermann, Elizabeth Brown, Adam Brufsky, Laurence Demers, Ravinder K. Grewal, Theresa Guise, Rebecca Jackson, Kevin McEnery, Donald Podoloff, Peter Ravdin, Charles L. Shapiro, Matthew Smith, and Catherine H. Van Poznak

possible advantage of SERMs compared with estrogen therapy is the lack of early increase in coronary heart disease and a significant reduction in hormone receptor-positive breast cancer. Results of the ongoing STAR trial (Study of Tamoxifen and Raloxifene

Full access

Linda Overholser and Carlin Callaway

.2019) recommend that women taking tamoxifen for invasive breast cancer should have an annual gynecologic assessment every 12 months. However, recommendations from the American College of Obstetricians and Gynecologists (ACOG) do not align with those from NCCN for